HUE042569T2 - Rákok és fibrózis kezelési eljárások - Google Patents

Rákok és fibrózis kezelési eljárások

Info

Publication number
HUE042569T2
HUE042569T2 HUE14702771A HUE14702771A HUE042569T2 HU E042569 T2 HUE042569 T2 HU E042569T2 HU E14702771 A HUE14702771 A HU E14702771A HU E14702771 A HUE14702771 A HU E14702771A HU E042569 T2 HUE042569 T2 HU E042569T2
Authority
HU
Hungary
Prior art keywords
fibrosis
cancers
treatment
methods
Prior art date
Application number
HUE14702771A
Other languages
English (en)
Inventor
Remy Hanf
Dean Hum
3
Benoît Noel
Original Assignee
Genfit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfit filed Critical Genfit
Publication of HUE042569T2 publication Critical patent/HUE042569T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HUE14702771A 2013-01-18 2014-01-20 Rákok és fibrózis kezelési eljárások HUE042569T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13305067 2013-01-18

Publications (1)

Publication Number Publication Date
HUE042569T2 true HUE042569T2 (hu) 2019-07-29

Family

ID=47628079

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE14702771A HUE042569T2 (hu) 2013-01-18 2014-01-20 Rákok és fibrózis kezelési eljárások

Country Status (26)

Country Link
US (2) US20150352065A1 (hu)
EP (1) EP2948137B1 (hu)
JP (1) JP6218854B2 (hu)
KR (1) KR102196277B1 (hu)
CN (1) CN105120855B (hu)
AU (1) AU2014206781B2 (hu)
CA (1) CA2897258C (hu)
CY (1) CY1121156T1 (hu)
DK (1) DK2948137T3 (hu)
EA (1) EA031718B1 (hu)
ES (1) ES2702038T3 (hu)
HK (1) HK1214773A1 (hu)
HU (1) HUE042569T2 (hu)
IL (1) IL239715B (hu)
LT (1) LT2948137T (hu)
MD (1) MD4629B1 (hu)
MX (1) MX361565B (hu)
NZ (1) NZ709420A (hu)
PH (1) PH12015501566B1 (hu)
PL (1) PL2948137T3 (hu)
PT (1) PT2948137T (hu)
SG (1) SG11201505281PA (hu)
SI (1) SI2948137T1 (hu)
TR (1) TR201819042T4 (hu)
WO (1) WO2014111584A1 (hu)
ZA (1) ZA201505151B (hu)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA031718B1 (ru) 2013-01-18 2019-02-28 Женфит Лечение фиброза и рака, связанных с тирозинкиназой
US11162097B2 (en) * 2016-02-23 2021-11-02 Nogra Pharma Limited Methods of treating intestinal fibrosis using SMAD7 inhibition
WO2018193007A1 (en) 2017-04-18 2018-10-25 Genfit Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor
EP3830070A1 (en) 2018-08-03 2021-06-09 Genfit Elafibranor salts
GB201901507D0 (en) * 2019-02-04 2019-03-27 St Georges Hospital Medical School New treatment
AU2021219286A1 (en) 2020-02-10 2022-09-22 Genfit Polymorphs of elafibranor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7736677B2 (en) * 2001-06-20 2010-06-15 Metaproteomics, Llc Xanthohumol and tetrahydro-isoalpha acid based protein kinase modulation cancer treatment
FR2841784B1 (fr) * 2002-07-08 2007-03-02 Composition a base de derives de 1,3-diphenylprop-2en-1-one substitues, preparation et utilisations
FR2841900B1 (fr) * 2002-07-08 2007-03-02 Genfit S A Nouveaux derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations
FR2857361B1 (fr) * 2003-07-08 2005-09-09 Genfit S A PREPARATION DE DERIVES DE 1,3-DIPHENYPROP-2-¼n-1-one
EP2641596B1 (en) * 2009-11-26 2018-05-02 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
ES2384060B1 (es) * 2010-03-24 2013-09-23 Lipotec S.A. Cápsulas de nanopartículas lipídicas.
EA031718B1 (ru) 2013-01-18 2019-02-28 Женфит Лечение фиброза и рака, связанных с тирозинкиназой

Also Published As

Publication number Publication date
TR201819042T4 (tr) 2019-01-21
KR20150114497A (ko) 2015-10-12
US10792277B2 (en) 2020-10-06
US20170239213A1 (en) 2017-08-24
CN105120855B (zh) 2019-05-07
CA2897258C (en) 2021-02-02
ES2702038T3 (es) 2019-02-27
EA031718B1 (ru) 2019-02-28
IL239715B (en) 2019-06-30
EP2948137B1 (en) 2018-11-14
SI2948137T1 (sl) 2019-01-31
LT2948137T (lt) 2018-12-27
CA2897258A1 (en) 2014-07-24
EP2948137A1 (en) 2015-12-02
PL2948137T3 (pl) 2019-02-28
JP2016506913A (ja) 2016-03-07
IL239715A0 (en) 2015-08-31
AU2014206781A1 (en) 2015-07-16
AU2014206781B2 (en) 2018-08-23
CN105120855A (zh) 2015-12-02
HK1214773A1 (zh) 2016-08-05
NZ709420A (en) 2020-04-24
SG11201505281PA (en) 2015-08-28
ZA201505151B (en) 2016-07-27
US20150352065A1 (en) 2015-12-10
PT2948137T (pt) 2018-12-20
MD20150076A2 (ro) 2015-11-30
DK2948137T3 (en) 2019-01-07
KR102196277B1 (ko) 2020-12-29
WO2014111584A1 (en) 2014-07-24
JP6218854B2 (ja) 2017-10-25
PH12015501566A1 (en) 2015-09-21
CY1121156T1 (el) 2020-05-29
MX361565B (es) 2018-12-11
EA201591345A1 (ru) 2015-11-30
PH12015501566B1 (en) 2015-09-21
MD4629B1 (ro) 2019-05-31
MX2015009251A (es) 2015-10-15

Similar Documents

Publication Publication Date Title
IL279767B (en) Medical polymeric nanoparticles, methods for their preparation and use
GB2535360B (en) Methods of preparing polyhemiaminals and polyhexahydrotriazines
GB2517079B (en) Security devices and methods of manufacture
EP2968397A4 (en) DIAGNOSIS AND TREATMENT OF FIBROSIS
GB201320723D0 (en) Composition and methods of treatment
HK1221611A1 (zh) 維持和改善肌肉功能的方法
EP2999474A4 (en) THERAPEUTIC AND METHOD OF USE
HK1224210A1 (zh) 用於治療纖維化的方法和組合物
HK1214773A1 (zh) 纖維化和癌症的治療方法
HK1224307A1 (zh) 原毒素- 變體及其使用方法
HK1220453A1 (zh) 治療運動障礙和相關病症的方法